Evommune, Inc. (EVMN)
Evommune, Inc. (EVMN) is a healthcare company (biotechnology) based in the United States. The share price is $7.11, up 0.14% on the day, which values the company at $294M. Price as of 17 Nov 2026, 19:16 UTC, from Yahoo Finance.
Key facts
- Share price
- $7.11+0.14% today
- Market value
- $294M
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Evommune, Inc. in more detail
EVMN trades at -2.1× next year's expected earnings.
In its favour: Altman Z in the safe zone; More cash than debt. Worth checking: Heavy stock-based pay.
2 of the superinvestors tracked here hold EVMN, including Peter Kolchinsky (0.4% of the portfolio), Julian and Felix Baker (0.1% of the portfolio).
Superinvestors holding EVMN
2 of the investors tracked here report a position in their latest 13F filing.
- Peter Kolchinsky RA Capital Management0.40% of portfolio · $46.4M · Q2 2026
- Julian and Felix Baker Baker Bros. Advisors0.06% of portfolio · $11.3M · Q2 2026
Evommune, Inc. (EVMN): questions and answers
What is Evommune, Inc.'s market cap?
Evommune, Inc. is valued at $294M at a share price of $7.11.
Does EVMN pay a dividend?
Evommune, Inc. does not currently pay a regular dividend.
Which famous investors own EVMN?
In their latest quarterly filings, Peter Kolchinsky (0.4% of the portfolio), Julian and Felix Baker (0.1% of the portfolio) hold EVMN. These filings are published up to 45 days after each quarter ends, so positions may have changed since.
When does Evommune, Inc. report earnings next?
Evommune, Inc.'s next earnings report is expected on November 16, 2026. The date comes from the market data feed and companies do move it.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Evommune, Inc. (EVMN) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/EVMN
Underlying data: Yahoo Finance; company filings with the SEC.